Climb Bio, Inc. (CLYM)
10.36
-0.51
(-4.69%)
USD |
NASDAQ |
Nov 13, 16:00
10.35
-0.01
(-0.10%)
Pre-Market: 09:14
Climb Bio Enterprise Value : 393.71M for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 393.71M |
| November 12, 2026 | 423.15M |
| November 11, 2026 | 502.82M |
| November 10, 2026 | 473.37M |
| November 09, 2026 | 431.23M |
| November 06, 2026 | 389.67M |
| November 05, 2026 | 307.69M |
| November 04, 2026 | 334.25M |
| November 03, 2026 | 358.50M |
| November 02, 2026 | 357.92M |
| October 30, 2026 | 387.36M |
| October 29, 2026 | 391.98M |
| October 28, 2026 | 379.85M |
| October 27, 2026 | 348.10M |
| October 26, 2026 | 304.23M |
| October 23, 2026 | 383.90M |
| October 22, 2026 | 404.10M |
| October 21, 2026 | 423.15M |
| October 20, 2026 | 419.11M |
| October 19, 2026 | 357.34M |
| October 16, 2026 | 362.54M |
| October 15, 2026 | 425.46M |
| October 14, 2026 | 389.67M |
| October 13, 2026 | 390.82M |
| October 12, 2026 | 420.84M |
| Date | Value |
|---|---|
| October 09, 2026 | 430.66M |
| October 08, 2026 | 422.57M |
| October 07, 2026 | 413.91M |
| October 06, 2026 | 412.18M |
| October 05, 2026 | 433.54M |
| October 02, 2026 | 427.19M |
| October 01, 2026 | 434.70M |
| September 30, 2026 | 457.79M |
| September 29, 2026 | 478.71M |
| September 28, 2026 | 492.49M |
| September 25, 2026 | 487.90M |
| September 24, 2026 | 501.11M |
| September 23, 2026 | 537.29M |
| September 22, 2026 | 634.36M |
| September 21, 2026 | 601.62M |
| September 18, 2026 | 625.17M |
| September 17, 2026 | 625.75M |
| September 16, 2026 | 628.62M |
| September 15, 2026 | 617.13M |
| September 14, 2026 | 654.46M |
| September 11, 2026 | 636.66M |
| September 10, 2026 | 676.86M |
| September 09, 2026 | 682.61M |
| September 08, 2026 | 731.43M |
| September 04, 2026 | 709.60M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Korsana Biosciences, Inc. | 1.011B |
| Cullinan Therapeutics, Inc. | 381.27M |
| Q32 Bio, Inc. | -24.10M |
| Oncolytics Biotech, Inc. | 46.90M |
| Sangamo Therapeutics, Inc. | 40.22M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -14.57M |
| Total Expenses (Quarterly) | 14.57M |
| EPS Diluted (Quarterly) | -0.1821 |
| Earnings Yield | -7.92% |
| Normalized Earnings Yield | -7.920 |